Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2017 Jul 11;16(10):2257–2266. doi: 10.1158/1535-7163.MCT-17-0179

Figure 2. Reducing ABCB1 expression re-sensitizes docetaxel-resistant cells to cabazitaxel treatment.

Figure 2

A. C4-2B, TaxR, DU145, DU145-DTXR, TaxR-Control and TaxR-shABCB1 whole cell lysates were subjected to western blot analysis using indicated antibodies. Tubulin served as a loading control. B. TaxR-Control and TaxR-shABCB1 cells were subjected to cell growth assays using either vehicle (DMSO) or cabazitaxel (1nM) treatment. Cells were counted 72 hours post-treatment. C. TaxR-Control and TaxR-shABCB1 cells were subjected to clonogenic assays using indicated doses of cabazitaxel. Colonies were allowed to form for 8 days post-treatment. Colonies were then stained with crystal violet and counted. D. TaxR-Control and TaxR-shABCB1 cells were treated with either vehicle (DMSO) or cabazitaxel (1nM) for 72 hours. Whole cell lysates were then prepared and subjected to western blot analysis using indicated antibodies. Tubulin served as a loading control. c-PARP = cleaved-PARP, C = control (DMSO) treatment, CTX = cabazitaxel. All data is presented as percent of control mean ± standard deviation. * = p-value ≤ 0.05.